CMS Grants Separate Medicare Payment for B. Braun Nerve Block Needles

The NOPAIN Act, a federal initiative designed to combat opioid dependency, incentivizes the use of non-opioid alternatives for surgical recovery. By providing temporary separate payment for qualifying devices, the legislation aims to reduce reliance on addictive pain medications. B. Braun’s needles, utilized in single-injection peripheral nerve block procedures, now fall under this coverage umbrella, supporting multimodal pain management strategies. Kristin Brown, Director of Pain Control Marketing at B. Braun, noted that the inclusion underscores the necessity of enabling technologies in modern, opioid-sparing clinical practices. While the current mandate remains active through December 31, 2027, providers are encouraged to consult their Medicare contractors regarding specific billing policies and documentation requirements as they navigate these reimbursement updates.